Literature DB >> 16375738

Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia.

S S Daskalopoulou1, V Tzovaras, D P Mikhailidis, M Elisaf.   

Abstract

Beyond allopurinol and the well-established uricosuric drugs, several other agents can decrease serum uric acid (SUA) levels, such as losartan, fenofibrate and some non-steroidal anti-inflammatory drugs (NSAIDs). Some of these drugs increase renal urate excretion. Hyperuricaemia and gout are common problems (at least 1% of Western men are affected by gout). Raised SUA levels increase the incidence of acute gout and renal calculi. Hyperuricaemia may also predict an increased risk of vascular events. Therefore, lowering SUA levels is of clinical relevance. In this review we consider the effect on SUA levels of drugs that are prescribed for indications other than treating hyperuricaemia. These drugs may obviate the need for specific treatment (e.g. allopurinol) aimed at lowering SUA levels. Furthermore, because hyperuricaemic patients may already be on several drugs (e.g. due to associated dyslipidaemia, hypertension and/or arthritis) compliance may be improved by avoiding additional medication. The potential for adverse effects associated with polypharmacy would also be decreased.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16375738     DOI: 10.2174/138161205774913309

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  20 in total

1.  Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome.

Authors:  Michael S Kostapano; Niki Katsiki; Vasilios G Athyros; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Oman Med J       Date:  2012-03

2.  Predicting allopurinol response in patients with gout.

Authors:  Daniel F B Wright; Stephen B Duffull; Tony R Merriman; Nicola Dalbeth; Murray L Barclay; Lisa K Stamp
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

3.  Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors.

Authors:  Lenka Hasikova; Marketa Pavlikova; Hana Hulejova; Petr Kozlik; Kveta Kalikova; Aparna Mahajan; Martin Herrmann; Blanka Stiburkova; Jakub Zavada
Journal:  Rheumatol Int       Date:  2019-07-31       Impact factor: 2.631

4.  Uric acid and chronic kidney disease: A time to act?

Authors:  Gianni Bellomo
Journal:  World J Nephrol       Date:  2013-05-06

Review 5.  Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.

Authors:  Arrigo F G Cicero; Matteo Pirro; Gerald F Watts; Dimitri P Mikhailidis; Maciej Banach; Amirhossein Sahebkar
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

6.  Serum Uric Acid Levels and Risk of Intracranial Atherosclerotic Stenosis: A Cross-Sectional Study.

Authors:  Lin Li; Jun-Xia Zhu; Xiao-He Hou; Ya-Hui Ma; Wei Xu; Chen-Chen Tan; Fu-Rong Sun; Hong-Qi Li; Qiang Dong; Lan Tan; Jin-Tai Yu
Journal:  Neurotox Res       Date:  2020-02-08       Impact factor: 3.911

Review 7.  Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Niki Katsiki; Michael Doumas; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 8.  Improving cardiovascular and renal outcomes in gout: what should we target?

Authors:  Pascal Richette; Fernando Perez-Ruiz; Michael Doherty; Tim L Jansen; George Nuki; Eliseo Pascual; Leonardo Punzi; Alexander K So; Thomas Bardin
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

9.  The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.

Authors:  Daniel F B Wright; Lisa K Stamp; Tony R Merriman; Murray L Barclay; Stephen B Duffull; Nicholas H G Holford
Journal:  Eur J Clin Pharmacol       Date:  2013-03-10       Impact factor: 2.953

10.  Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors.

Authors:  A P Schmidt; A E Böhmer; C Antunes; C Schallenberger; L O Porciúncula; E Elisabetsky; D R Lara; D O Souza
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.